AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Fulcrum Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00DDY1RM7
3.68▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
3.68
Day's Range
3.64 – 3.69
52-Week Range
2.83 – 15.74
Volume
1.1M
Avg Volume
1.4M
Share Statistics
Shares Outstanding
Employees
55
Exchange
XNAS
Listed
2019-07-18
Share count as of July 23, 2026

Fulcrum Therapeutics, Inc. Common Stock (FULC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Fulcrum Therapeutics, Inc. Common Stock (FULC)
What is Fulcrum Therapeutics, Inc. Common Stock's Market Cap?
Fulcrum Therapeutics, Inc. Common Stock's Market Cap is $280.8M, based on as-reported figures from SEC (XBRL) filings.
What is Fulcrum Therapeutics, Inc. Common Stock's Revenue (TTM)?
Fulcrum Therapeutics, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Fulcrum Therapeutics, Inc. Common Stock's Net Income (TTM)?
Fulcrum Therapeutics, Inc. Common Stock's Net Income (TTM) is -$85.0M, based on as-reported figures from SEC (XBRL) filings.
What is Fulcrum Therapeutics, Inc. Common Stock's EBITDA?
Fulcrum Therapeutics, Inc. Common Stock's EBITDA is -$94.8M, based on as-reported figures from SEC (XBRL) filings.
What is Fulcrum Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Fulcrum Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.11, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · FULCAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue——
YoY growth————
Operating expenses:
Research and development
General and administrative
Impairment of long-lived assets———
Restructuring expenses—
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Other income, net
Net loss
% of revenue————
Net loss per share, basic—
Net loss per share, diluted—